These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35765222)

  • 21. RT001 in Progressive Supranuclear Palsy-Clinical and In-Vitro Observations.
    Angelova PR; Andruska KM; Midei MG; Barilani M; Atwal P; Tucher O; Milner P; Heerinckx F; Shchepinov MS
    Antioxidants (Basel); 2021 Jun; 10(7):. PubMed ID: 34202031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease.
    Gibbons C; Pagnini F; Friede T; Young CA
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011005. PubMed ID: 29293261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
    Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
    BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial).
    Salamone P; Fuda G; Casale F; Marrali G; Lunetta C; Caponnetto C; Mazzini L; La Bella V; Mandrioli J; Simone IL; Moglia C; Calvo A; Tarella C; Chio A;
    BMJ Open; 2020 Mar; 10(3):e034049. PubMed ID: 32209625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2003; (4):CD003457. PubMed ID: 14583978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WITHDRAWN: Amino acids for amyotrophic lateral sclerosis / motor neuron disease.
    Parton M; Mitsumoto H; Leigh PN
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003457. PubMed ID: 18425887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
    Mitchell JD; Wokke JH; Borasio GD
    Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.
    Dalbello-Haas V; Florence JM; Krivickas LS
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005229. PubMed ID: 18425913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
    Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
    Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutral Lipid Cacostasis Contributes to Disease Pathogenesis in Amyotrophic Lateral Sclerosis.
    Dodge JC; Jensen EH; Yu J; Sardi SP; Bialas AR; Taksir TV; Bangari DS; Shihabuddin LS
    J Neurosci; 2020 Nov; 40(47):9137-9147. PubMed ID: 33051352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
    Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.
    McDermott CJ; Bradburn MJ; Maguire C; Cooper CL; Baird WO; Baxter SK; Cohen J; Cantrill H; Dixon S; Ackroyd R; Baudouin S; Bentley A; Berrisford R; Bianchi S; Bourke SC; Darlison R; Ealing J; Elliott M; Fitzgerald P; Galloway S; Hamdalla H; Hanemann CO; Hughes P; Imam I; Karat D; Leek R; Maynard N; Orrell RW; Sarela A; Stradling J; Talbot K; Taylor L; Turner M; Simonds AK; Williams T; Wedzicha W; Young C; Shaw PJ
    Health Technol Assess; 2016 Jun; 20(45):1-186. PubMed ID: 27353839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.
    Ashworth NL; Satkunam LE; Deforge D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD004156. PubMed ID: 22336799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.
    Ashworth NL; Satkunam LE; Deforge D
    Cochrane Database Syst Rev; 2004; (1):CD004156. PubMed ID: 14974059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.
    Ashworth NL; Satkunam LE; Deforge D
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004156. PubMed ID: 16437474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2007 Jan; (1):CD001447. PubMed ID: 17253460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.